Atossa Therapeutics (ATOS) Long-Term Debt Issuances (2011 - 2012)
Atossa Therapeutics (ATOS) posted quarterly Long-Term Debt Issuances of -$80453.0 for Q4 2012, down 1534.56% year-over-year from $5608.2 in Q1 2012, and down 198.65% quarter-over-quarter from $81553.0 in Q3 2012.
Atossa Therapeutics (ATOS) Long-Term Debt Issuances (2011 - 2012) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Long-Term Debt Issuances for 2 consecutive years, with -$80453.0 the latest figure, recorded in Q4 2012.
- In Q4 2012, Long-Term Debt Issuances fell 1534.56% year-over-year to -$80453.0; the TTM figure through Sep 2013 stood at -$80453.0 (down 214.19% YoY), while the FY2012 annual figure was -$5078.0, up 97.24% from the prior year.
- Long-Term Debt Issuances eased to -$80453.0 in Q4 2012 per ATOS's latest filing, from $81553.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $81553.0 in Q3 2012 and bottomed at -$80453.0 in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -80,453.00 |
| Dec 31, 2012 | -80,453.00 |
| Sep 30, 2012 | 81,553.00 |
| Sep 30, 2012 | 81,553.00 |
| Mar 31, 2012 | -6,178.00 |
| Mar 31, 2012 | -6,178.00 |
| Dec 31, 2011 | -4,922.00 |
| Dec 31, 2011 | -4,922.00 |